Perspectum Ltd: Company Profile

Background

Overview

Perspectum Ltd, established in 2012, is a UK-based medical technology company specializing in precision health solutions. The company focuses on developing non-invasive imaging technologies that assist healthcare providers in diagnosing and monitoring chronic systemic diseases, including liver and bile diseases, long COVID, diabetes, and cancer. By leveraging advanced imaging and quantitative assessments, Perspectum aims to enhance early detection, diagnosis, and targeted treatment, thereby improving patient outcomes.

Mission and Vision

Perspectum's mission is to empower patients and clinicians through innovative digital technologies, enabling a better understanding of complex health conditions. The company's vision is to build a future where precision medicine is accessible to all, facilitating personalized medical care tailored to individual needs.

Industry Significance

Operating within the medical technology sector, Perspectum has made significant contributions to the field of precision health. Its innovative imaging solutions have been recognized for their impact on early disease detection and management, positioning the company as a key player in advancing non-invasive diagnostic technologies.

Key Strategic Focus

Core Objectives

Perspectum is dedicated to developing and delivering cutting-edge digital technologies that aid clinicians in providing better care for patients with chronic systemic diseases. The company's primary objectives include:

• Advancing non-invasive imaging solutions for early disease detection.

• Enhancing diagnostic accuracy and monitoring capabilities.

• Supporting personalized treatment plans through quantitative assessments.

Areas of Specialization

The company specializes in:

• Non-invasive imaging technologies.

• Quantitative assessment tools for chronic diseases.

• Clinical decision support systems.

Key Technologies Utilized

Perspectum employs proprietary technologies, including:

• Multiparametric MRI imaging.

• Advanced data analytics platforms.

• Biomarker extraction from imaging data.

Primary Markets Targeted

The company's solutions are primarily targeted at:

• Healthcare providers and clinicians.

• Pharmaceutical companies conducting clinical trials.

• Research institutions focusing on chronic diseases.

Financials and Funding

Funding History

Perspectum has secured substantial funding through multiple investment rounds:

• Series C Round (March 2023): Raised $19 million, co-led by Oppenheimer & Co.

• Series C Round (January 2023): Raised £31 million, with participation from The Blue Venture Fund and Oppenheimer & Co.

• Series B Round (April 2020): Raised $35.86 million, led by the University of Oxford and The Blue Venture Fund.

• Venture Round (January 2017): Raised $15.75 million.

• Venture Round (January 2016): Received €4.89 million from the EU Executive Agency for SMEs.

Total Funds Raised

The company has raised a total of approximately $147 million across various funding rounds.

Notable Investors

Investors include:

• Oppenheimer & Co.

• The Blue Venture Fund

• University of Oxford

• Puhua Capital

• Oxford Science Innovation

• NHS England

• Innovate UK

Utilization of Capital

The funds have been allocated towards:

• Commercialization of LiverMultiScan® for clinical use.

• Expansion of the Contract Research Organization (CRO) business.

• Development of additional products for biliary disease, diabetes, and cancer.

• Enhancing research and development capabilities.

Pipeline Development

Key Pipeline Candidates

Perspectum's pipeline includes:

• LiverMultiScan®: A non-invasive imaging solution for detecting chronic liver disease.

• MRCP+: An imaging technology for quantitative biliary system assessment.

• cT1 Biomarker: A patented biomarker for assessing non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).

Stages of Development

• LiverMultiScan®: Commercialized and in clinical use.

• MRCP+: Recently introduced to the clinical product portfolio.

• cT1 Biomarker: Patented and utilized in clinical trials.

Target Conditions

• Chronic liver diseases (e.g., NAFLD, NASH).

• Biliary system disorders.

• Metabolic diseases.

• Cancer.

Anticipated Milestones

• Expansion of clinical applications for LiverMultiScan®.

• Broader adoption of MRCP+ in clinical settings.

• Integration of cT1 biomarker in more clinical trials.

Technological Platform and Innovation

Proprietary Technologies

• Multiparametric MRI Imaging: Enables comprehensive tissue characterization.

• Advanced Data Analytics: Processes complex imaging data for actionable insights.

• Biomarker Extraction: Identifies disease-specific biomarkers from imaging data.

Significant Scientific Methods

• Quantitative Imaging: Provides precise measurements of tissue properties.

• Data Fusion: Combines multiple imaging modalities for enhanced diagnostics.

• AI Integration: Utilizes artificial intelligence for pattern recognition and predictive analytics.

Leadership Team

Executive Profiles

• Dr. Rajarshi Banerjee: Chief Executive Officer & Founder. Dr. Banerjee has a background in biomedical engineering and has been instrumental in leading Perspectum's strategic direction and growth.

• Dr. Michael Brady: Founder, Chairman & Image Analysis Team Lead. A renowned physician and scientist, Dr. Brady has contributed significantly to the development of Perspectum's imaging technologies.

• Keri Hildick: Chief Revenue Officer. Ms. Hildick oversees revenue generation strategies and has a strong background in commercial operations within the healthcare sector.

• Rexford Newbould: Chief Operating Officer. Mr. Newbould manages day-to-day operations and has extensive experience in operational management in medical technology companies.

• Matthew Robson: Chief Technology Officer. Mr. Robson leads the technology development team, focusing on advancing Perspectum's imaging solutions.

Leadership Changes

• January 2026: Dr. Carmine Daniel Circelli and Mr. Samuel Eric Brasch were appointed as directors.

• January 2026: Ms. Ellen Marcia Zane's director details were updated.

• January 2026: Mr. Robert Steven Lowenthal was appointed as a director.

• January 2026: Dr. Michael Rosenblatt was appointed as a director.

• December 2025: Dr. Garheng Kong resigned as a director.

• December 2025: Dr. Rajarshi Banerjee resigned as a director.

• December 2025: Mr. Kevin Jong Lin Lim resigned as a director.

• December 2025: Mr. Thomas Hawes resigned as a director.

Competitor Profile

Market Insights and Dynamics

The medical imaging market is experiencing significant growth, driven by advancements in non-invasive diagnostic technologies and an increasing prevalence of chronic diseases. The demand for precision health solutions is rising, presenting opportunities for companies like Perspectum to expand their market presence.

Competitor Analysis

Key competitors include:

• Cerebriu: Specializes in AI-powered radiology solutions.